Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Balena

Showing results (21-30 of 33) with videos related to

Pageof 4
Sort By:
Bone|May 1, 1993
The aminobisphosphonate alendronate inhibits bone loss induced by thyroid hormone in the rat. Comparison between effects on tibiae and vertebraeR Balena, A Markatos, M Gentile, et al.
Diabetes, Obesity & Metabolism|August 6, 2013
A direct comparison of long- and short-acting GLP-1 receptor agonists (taspoglutide once weekly and exenatide twice daily) on postprandial metabolism after 24 weeks of treatmentA Gastaldelli, B Balas, R Ratner, et al.
Diabetic Medicine : a Journal of the British Diabetic Association|September 4, 2012
Taspoglutide, a once-weekly glucagon-like peptide 1 analogue, vs. insulin glargine titrated to target in patients with Type 2 diabetes: an open-label randomized trialM Nauck, E Horton, M Andjelkovic, et al.
The Journal of Pharmacology and Experimental Therapeutics|January 1, 1996
Long-term safety of the aminobisphosphonate alendronate in adult dogs. II. Histomorphometric analysis of the L5 vertebraeR Balena, A Markatos, J G Seedor, et al.
Journal of Endocrinological Investigation|July 6, 2000
Prevention of early postmenopausal bone loss with cyclical etidronateS Adami, V Bruni, D Bianchini, et al.
Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA|December 16, 1998
Effects of different regimens of sodium fluoride treatment for osteoporosis on the structure, remodeling and mineralization of boneR Balena, M Kleerekoper, J A Foldes, et al.
The EMBO Journal|March 1, 1994
Interleukin-6 deficient mice are protected from bone loss caused by estrogen depletionV Poli, R Balena, E Fattori, et al.
Journal of the American Society of Nephrology : JASN|June 30, 1998
Mineralized bone loss at different sites in dialysis patients: implications for preventionH C Schober, Z H Han, A J Foldes, et al.
The Journal of Clinical Investigation|May 1, 1995
Comparison of alendronate and sodium fluoride effects on cancellous and cortical bone in minipigs. A one-year studyM H Lafage, R Balena, M A Battle, et al.
Endocrinology|April 1, 1995
Bone density is normal in male rats treated with finasterideH N Rosen, S Tollin, R Balena, et al.
Pageof 4

Showing results (21-30 of 33) with videos related to

Sort By:
Pageof 4
Bone|May 1, 1993
The aminobisphosphonate alendronate inhibits bone loss induced by thyroid hormone in the rat. Comparison between effects on tibiae and vertebraeR Balena, A Markatos, M Gentile, et al.
Diabetes, Obesity & Metabolism|August 6, 2013
A direct comparison of long- and short-acting GLP-1 receptor agonists (taspoglutide once weekly and exenatide twice daily) on postprandial metabolism after 24 weeks of treatmentA Gastaldelli, B Balas, R Ratner, et al.
Diabetic Medicine : a Journal of the British Diabetic Association|September 4, 2012
Taspoglutide, a once-weekly glucagon-like peptide 1 analogue, vs. insulin glargine titrated to target in patients with Type 2 diabetes: an open-label randomized trialM Nauck, E Horton, M Andjelkovic, et al.
The Journal of Pharmacology and Experimental Therapeutics|January 1, 1996
Long-term safety of the aminobisphosphonate alendronate in adult dogs. II. Histomorphometric analysis of the L5 vertebraeR Balena, A Markatos, J G Seedor, et al.
Journal of Endocrinological Investigation|July 6, 2000
Prevention of early postmenopausal bone loss with cyclical etidronateS Adami, V Bruni, D Bianchini, et al.
Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA|December 16, 1998
Effects of different regimens of sodium fluoride treatment for osteoporosis on the structure, remodeling and mineralization of boneR Balena, M Kleerekoper, J A Foldes, et al.
The EMBO Journal|March 1, 1994
Interleukin-6 deficient mice are protected from bone loss caused by estrogen depletionV Poli, R Balena, E Fattori, et al.
Journal of the American Society of Nephrology : JASN|June 30, 1998
Mineralized bone loss at different sites in dialysis patients: implications for preventionH C Schober, Z H Han, A J Foldes, et al.
The Journal of Clinical Investigation|May 1, 1995
Comparison of alendronate and sodium fluoride effects on cancellous and cortical bone in minipigs. A one-year studyM H Lafage, R Balena, M A Battle, et al.
Endocrinology|April 1, 1995
Bone density is normal in male rats treated with finasterideH N Rosen, S Tollin, R Balena, et al.
Pageof 4